Trajan Group (ASX:TRJ) has reported its half year results for the 2023 financial year, showing revenue of $80.1M, up 83.2% from the previous corresponding period, and normalised EBITDA of $10.3M, up 115.9%.
Its Analytical Product and Life Science segments both reported improved revenue and proforma gross profit on PCP.
Trajan Group also says its made four acquisitions and one strategic investment since July 2021, and has a cash reserve of $21.1M.
The global analytical science and device company has also upgraded guidance for the full year FY2023, expecting revenue between $155.0M-$165.0M and normalised EBITDA between $21.7M-$25.8M.